Predominance of the Luminal B molecular subtype in a group of women with infiltrating breast cancer from the coffee region of Colombia: Analysis by immunohistochemistry


Authors

  • Paula Andrea Toro-Castaño Cleveland Clinic
  • Juliana Pava-De Los Ríos Universidad de Manizales
  • Camilo Celis-Montoya E.S.E. Hospital San Camilo – Buenavista
  • Sebastián Chica-Gómez Unión de Cirujanos, Manizales
  • Andrés Felipe Mejía-Jiménez
  • Manuel Villegas-Jaramillo IPS interconsultas
  • Édgar Fernando Pérez-Gaviria E.S.E. Hospital San Félix
  • Juan Paulo Preciado-Mosos IPS Virrey Solís
  • Álex Enrique Pava-Ripoll Universidad de Caldas

DOI:

https://doi.org/10.22517/25395203.25015

Keywords:

Breast Cancer, Immunohistochemistry, Prognosis

Abstract

Breast cancer is the most common cancer in women and constitutes a public health problem due to its high rates of morbidity and mortality. Diagnosis is made through routine histopathology studies that are complemented by expression studies of hormone receptors (Estrogen and Progesterone Receptors), human epidermal growth factor 2 (HER2) and cell proliferation index (Ki67) for their subtyping into molecular groups (Luminal A, Luminal B, Her2 and triple negative), which have different prognostic and therapeutic implications. Globally, a high prevalence of the Luminal A subtype has been reported, predominantly in North America, Europe, and some Latin American countries; however, the reports in the Colombian population are heterogeneous. The objective of this research is to establish an incidence profile of these molecular subtypes in a population of the coffee region in Colombia. In retrospect, samples of 377 patients with a diagnosis of infiltrating breast cancer were analyzed, between the years 2015 and 2018. The histological diagnoses included: NOS infiltrating ductal carcinomas (339 cases; 89.9 %), infiltrating lobular (23 cases; 6.1%), infiltrating mucinous (6 cases; 1.5%), infiltrating papillary (1 case; 0.2%) and mixed patterns: ductal - lobular (3 cases; 0.7%) and ductal with mucinous component (5 cases; 1.3%), of which 56.2% (212 cases) correspond to luminal B, 22.2% (84 cases) to Luminal A, 14.8% (56 cases) to triple negative and 6.6% (25 cases) to HER2. These findings contrast with the prevalence reported worldwide. Therefore, in the population of the Colombian coffee region, this predominance of the luminal pattern B should be considered when establishing prognosis and treatment from medical staff.

Downloads

Download data is not yet available.

Author Biographies

Paula Andrea Toro-Castaño, Cleveland Clinic

Médica y Cirujana.

Especialista en patología anatómica y clínica.

Magíster en genética médica.

Juliana Pava-De Los Ríos, Universidad de Manizales

Médica.

Camilo Celis-Montoya, E.S.E. Hospital San Camilo – Buenavista

Médico.

Sebastián Chica-Gómez, Unión de Cirujanos, Manizales

Médico.

Andrés Felipe Mejía-Jiménez

Médico.

Manuel Villegas-Jaramillo, IPS interconsultas

Médico. 

Édgar Fernando Pérez-Gaviria, E.S.E. Hospital San Félix

Médico.

Juan Paulo Preciado-Mosos, IPS Virrey Solís

Médico.

 

Álex Enrique Pava-Ripoll, Universidad de Caldas

Médico y Cirujano.

Especialista en patología.

References

Toriola AT, Colditz GA. Trends in breast cancer incidence and mortality in the United States: Implications for prevention. Breast Cancer Res Treat 2013;138:665–73. https://doi.org/10.1007/s10549-013-2500-7

Justo, N. Wilking, N. Jonsson B. A Review of Breast Cancer Care and Outcomes in Latin America. Oncologist 2013;18:248–56.

Ministerio de Salud. Cáncer de Mama, una enfermedad en ascenso en Colombia. [Internet] 2014. [citado 14 de Julio 2020].Disponible en: https://www.minsalud.gov.co/Paginas/-Cancer-de-mama,-una-enfermedad-en-ascenso-en-Colombia.aspx

Prat A, Cheang MCU, Galván P, Nuciforo P, Paré L, Adamo B, et al. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. JAMA Oncol 2016;2:1287–94. https://doi.org/10.1001/jamaoncol.2016.0922.

Glück S, De Snoo F, Peeters J, Stork-Sloots L, Somlo G. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat 2013;139:759–67. https://doi.org/10.1007/s10549-013-2572-4.

Pandit P, Patil R, Palwe V, Gandhe S, Patil R, Nagarkar R et al. Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients. Eur J Breast Heal 2020;16:39–43. https://doi.org/10.5152/ejbh.2019.4997.

National Cancer Institute-NIH. Cancer stat facts: Female breast cancer subtypes. [Internet] 2017. [citado 12 de Julio 2020] Disponible en: https://seer.cancer.gov/statfacts/html/breast-subtypes.html

Medina Bueno GA. Clinical and prognostic characteristics of the molecular subtypes of breast cancer determined by immunohistochemistry. Arequipa, Peru. Rev Peru Med Exp Salud Publica 2017;34:472–7. https://doi.org/10.17843/rpmesp.2017.343.2530

Reigosa A, Hardisson D, Sanz F, Caleiras E, Saldivia F, Fernández Á. Subclasificación de los tipos moleculares de cáncer de mama de acuerdo a la expresión de marcadores inmunohistoquímicos y evolución. Investig Clin 2016;57:187–216.

Ramírez Valle M, García Montesino G, Lores Hechevarria C, Sánchez Azcuy Y, Márquez Hernández C. Histología e inmunohistoquímica del cáncer de mama invasivo en la provincia de Pinar del Río.Rev Ciencias Médicas 2019; 23(1): 71-78. Disponible en: http://revcmpinar .sld.cu/index.php/publicaciones/article/view/3801

San EN, Tucumán MDE, Lara D, Griselda J, Carlos N, Alba L, et al. Y SUBTIPOS MOLECULARES MÁS FRECUENTES DE CARCINOMA MAMARIO ENTRE LOS AÑOS 2007 Y 2012 2012:76–81.

Pérez-Rodríguez G. Prevalence of breast cancer sub-types by immunohistochemistry in patients in the Regional General Hospital 72, Instituto Mexicano del Seguro Social. Cir Cir. 2015;83(3):193-198. doi:10.1016/j.circir.2015.05.003

Serrano-Gomez SJ, Sanabria-Salas MC, Hernández-Suarez G, García O, Silva C, Romero A, et al. High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. Carcinogenesis 2016;37:669–76. https://doi.org/10.1093/carcin/bgw043

Bonilla-Sepúlveda O, Matute-Turízo G, Severiche C. Classification of intrinsic subtypes of breast carcinomas analyzed in a pathology center of Medellin in 2011. CES Med. [Internet]. 2015 [citado 06 de julio 2022] ; 29( 1 ): 36-45. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-87052015000100004&lng=en.

Gómez R, Ossa CA, Montoya ME, Echeverri C, Ángel G, Ascuntar J, et al. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy. Ecancer. 2015;9. https://doi.org/10.3332/ecancer.2015.562.

Jaramillo J. Clasificación molecular del cáncer de mama por técnica de inmunohistoquímica en Magdalena, Colombia. Revista Colombiana de Patología; 20191(7) 23-29

Wolff AC, Elizabeth Hale Hammond M, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/ college of American pathologists clinical practice guideline focused update. J Clin Oncol 2018;36:2105–22. https://doi.org/10.1200/JCO.2018.77.8738.

Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in Breast Cancer: Recommendations from the international Ki67 in breast cancer working Group. J Natl Cancer Inst 2011;103:1656–64. https://doi.org/10.1093/jnci/djr393.

Downloads

Published

2022-10-30 — Updated on 2022-12-29

Versions

How to Cite

Toro-Castaño, P. A., Pava-De Los Ríos, J., Celis-Montoya, C. ., Chica-Gómez, S., Mejía-Jiménez, A. F., Villegas-Jaramillo, M., Pérez-Gaviria, Édgar F., Preciado-Mosos, J. P. ., & Pava-Ripoll, Álex E. (2022). Predominance of the Luminal B molecular subtype in a group of women with infiltrating breast cancer from the coffee region of Colombia: Analysis by immunohistochemistry. Revista Médica De Risaralda, 28(2). https://doi.org/10.22517/25395203.25015 (Original work published October 30, 2022)

Issue

Section

Original Article